|
|
|
| Telomerase reactivation is associated with hepatobiliary and pancreatic cancers |
| Vito Sansone a , ∗, Marco Le Grazie b , Jenny Roselli b , Simone Polvani b , Andrea Galli b , Francesco Tovoli a , Mirko Tarocchi b |
a Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
b Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Firenze, Italy
∗ Corresponding author.
E-mail address: vito.sansone@studio.unibo.it (V. Sansone). |
|
|
|
Abstract Background: Human telomerase reverse transcriptase (hTERT) and its components play a significant role in cancer progression, but recent data demonstrated that telomeres and telomerase alterations could be found in other diseases; increasing evidence suggests a key role of this enzyme in the fields of hepatobiliary and pancreatic diseases.
Data sources: We performed a PubMed search with the following keywords: telomerase, hepatocellular carcinoma, cholangiocarcinoma, pancreatic adenocarcinoma by December 2019. We reviewed the relevant publications that analyzed the correlation between telomerase activity and hepatobiliary and pancreatic diseases.
Results: Telomerase reactivation plays a significant role in the development and progression of hepatobiliary and pancreatic tumors and could be used as a diagnostic biomarker for hepatobiliary and pancreatic cancers, as a predictor for prognosis and a promising therapeutic target.
Conclusions: Our review summarized the evidence about the critical role of hTERT in cancerous and precancerous lesions of the alteration and its activity in hepatobiliary and pancreatic diseases.
|
|
|
|
|
|
|
|
|
2020, Vol. 19 
